Evolent Health, Inc (EVH) News

Evolent Health, Inc (EVH): $8.27

0.18 (-2.13%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add EVH to Watchlist
Sign Up

Industry: Medical - Services

Industry

C

Ranked

#61 of 63

in industry

Filter EVH News Items

EVH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EVH News Highlights

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

Latest EVH News From Around the Web

Below are the latest news stories about EVOLENT HEALTH INC that investors may wish to consider to help them evaluate EVH as an investment opportunity.

High Growth Tech Stocks In The United States To Watch

The United States market has remained flat over the past week but has seen a significant rise of 23% in the last year, with earnings expected to grow by 15% annually in the coming years. In this context, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to capitalize on these favorable market conditions.

Yahoo | January 9, 2025

Evolent Health, Inc. (NYSE:EVH): Are Analysts Optimistic?

We feel now is a pretty good time to analyse Evolent Health, Inc.'s ( NYSE:EVH ) business as it appears the company may...

Yahoo | January 1, 2025

New Strong Sell Stocks for December 26th

ATI, BATRA and EVH have been added to the Zacks Rank #5 (Strong Sell) List on December 26, 2024.

Yahoo | December 26, 2024

Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025.

Yahoo | December 18, 2024

Hedge Funds Think That Evolent Health, Inc. (EVH) Will Bounce Back Soon

We recently compiled a list of the 10 Stocks That Will Bounce Back According To Hedge Funds. In this article, we are going to take a look at where Evolent Health, Inc. (NYSE:EVH) stands against the other stocks. With 2024 coming to a close, investors have left several unknown variables behind them. They started out the […]

Yahoo | December 18, 2024

New Strong Sell Stocks for December 12th

ASH, BIDU and EVH have been added to the Zacks Rank #5 (Strong Sell) List on December 12, 2024.

Yahoo | December 12, 2024

Exploring Three High Growth Tech Stocks In The United States

The United States market has shown impressive momentum, climbing 1.6% in the last seven days and 32% over the past year, with earnings forecasted to grow by 15% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions.

Yahoo | November 28, 2024

Evolent Health, Inc. (EVH): This Small-Cap Stock Is Ready To Explode

We recently compiled a list of the 10 Best Small-Cap Stocks Ready To Explode. In this article, we are going to take a look at where Evolent Health, Inc. (NYSE:EVH) stands against the other small-cap stocks. Prospects For Extended Outperformance Of Small-Cap Stocks On October 7, Chuck Royce, founder and Senior Advisor, and Francis Gannon, Co-Chief […]

Yahoo | November 19, 2024

Evolent Health Third Quarter 2024 Earnings: EPS Misses Expectations

Evolent Health ( NYSE:EVH ) Third Quarter 2024 Results Key Financial Results Revenue: US$621.4m (up 22% from 3Q 2023...

Yahoo | November 9, 2024

Evolent Health downgraded at Stephens amid surging cancer costs

As previously reported, Stephens analyst Jeff Garro downgraded Evolent Health (EVH) to Equal Weight from Overweight with a price target of $16, down from $38. Rising oncology costs are stressing Evolent’s profitability and exposing timing issues inherent to its at-risk Performance Suite business, the analyst tells investors in a research note. While the firm thinks these weaknesses can be remedied, improving contractual protections across the entire book will take time, the analyst added. Publis

Yahoo | November 9, 2024


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!